US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Celldex Therapeutics, Inc.

< Previous 1 2 3 Next >
News headline image
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex to Present at Upcoming Investor Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Reports Second Quarter Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Announces Planned Transition of Chief Financial Officer
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Reports First Quarter Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex to Present at Upcoming Investor Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Announces Proposed Public Offering of Common Stock
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex to Present at Upcoming Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex to Present at Upcoming Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
< Previous 1 2 3 Next >